Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ethicon Gains PMA For SEDASYS; Opens New Opportunity In GI Medicine

Executive Summary

Ethicon finally received FDA approval in May for its SEDASYS System, a computer-assisted personalized sedation system that allows physician-led teams to safely administer the anesthetic agent propofol during certain gastroenterology procedures, including colonoscopy. The approval opens up a whole new product category for the company with a market potential of 15 million procedures in the US alone.

You may also be interested in...



Six Devices, Diagnostics Among Cleveland Clinic’s Top 10 Innovations For 2014

At its October Medical Innovation Summit, the Cleveland Clinic unveiled six device and diagnostics products that were selected for inclusion in its list of top 10 innovations for 2014.

Six Devices, Diagnostics Among Cleveland Clinic’s Top 10 Innovations

At its 2013 Innovation Summit, the Cleveland Clinic unveiled six devices and diagnostics among its top 10 innovations.

J&J Gets Second Chance At Sedasys Sedation Device Approval

Johnson & Johnson subsidiary Ethicon Endo-Surgery has received a go-ahead from the FDA commissioner's office to embark on a rarely used process to appeal a PMA denial by the agency’s device center.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT035640

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel